One of the most common questions about GLP-1 medications isn't about starting them, it's about what happens when you stop. The research on this question has grown substantially, and it tells a more nuanced story than either "you'll regain everything" or "the results are permanent."
What the Clinical Trial Extension Data Showed
The most widely cited controlled data on this question comes from an extension of the STEP 1 trial, which followed participants who had been on semaglutide for weight management after they stopped taking it. That extension study found that participants regained a substantial portion of their lost weight within roughly a year of discontinuation, and that improvements in cardiometabolic markers like blood pressure and blood sugar control that had occurred on the drug also moved back toward baseline. This is trial-population data, meaning participants were monitored and had stopped the medication in a controlled research context, not necessarily reflecting how weight trends when people stop treatment for other reasons, like cost, side effects, or supply issues, in the real world.
What Newer Real-World Data Shows
A more recent real-world analysis from Epic Research, examining electronic health record data from over 20,000 patients who had been prescribed semaglutide and a separate group of nearly 18,000 prescribed liraglutide, found a somewhat different pattern one year after discontinuation. Roughly 56% of patients in both groups either maintained roughly the same weight they were at when they stopped the medication or continued to lose additional weight, while about 18% regained all of their lost weight or more. That leaves a substantial middle group who experienced partial regain, neither losing further nor returning fully to their starting weight.
Why the Two Pictures Differ
Clinical trial populations and real-world patient populations differ in ways that plausibly explain some of the gap: trial participants in an extension study are specifically being followed for a defined discontinuation period, while real-world patients who stop a medication do so for varied reasons, at varied times, and often continue other lifestyle changes, follow-up care, or occasionally restart treatment, all of which the aggregate real-world numbers can't fully separate out. Neither dataset is "wrong"; they're answering related but not identical questions.
Why Weight Regain Happens Biologically
GLP-1 drugs work in large part by altering appetite signaling and satiety, mechanisms that are actively suppressing hunger cues while the drug is present in the body. Obesity research more broadly has documented that the body's hunger and metabolic-rate signaling tends to shift to defend a higher weight after weight loss, regardless of the method used to lose it, a phenomenon sometimes described as metabolic adaptation. Stopping a drug that was actively counteracting those signals removes that counterbalance, which is the mechanistic reason regain is common across weight-loss methods generally, not a flaw unique to GLP-1 drugs specifically.
What This Means for Planning Treatment
Because both trial and real-world data point toward regain being common, though not universal or complete, many physicians now discuss GLP-1 therapy for obesity as a potentially long-term or indefinite treatment, similar to how blood pressure or cholesterol medications are typically managed, rather than a short course meant to be stopped once a weight goal is reached. Anyone considering stopping a GLP-1 medication, whether for cost, side effects, or any other reason, should talk to their prescribing physician about tapering strategies, whether a lower maintenance dose is appropriate, and what to expect, rather than stopping abruptly without a plan.
The Bottom Line
Weight regain after stopping a GLP-1 medication is common but not universal or complete for everyone, with roughly half of real-world patients in one large dataset maintaining their weight loss a year out. The honest takeaway from the research so far is that these drugs generally need to keep being taken to keep working, which is a meaningful consideration for anyone weighing the decision to start one, and a conversation worth having with a physician before beginning or ending treatment.